HBIO

Business Context and Reporting Period

Company: Harvard Bioscience, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2009
Business Overview: The Company manufactures and sells apparatus, instruments, devices, and consumables for life science research. Operations are focused on the Apparatus and Instrumentation business segment following the divestiture of the Capital Equipment Business segment, which is reported as discontinued operations.

Key Financial Metrics

Note: Q1 2008 Net Income included a $0.5 million loss from discontinued operations. Q1 2009 had no discontinued operations.

Material Changes vs. Prior Period

• Revenue Decline: Revenues decreased 13.1% to $19.1 million. Management attributes the entire decrease to the strengthening of the U.S. dollar against foreign currencies (primarily the British Pound and Euro). Organic growth was flat (0%) in constant currency.
• Profitability Improvement: Despite lower revenue, Net Income increased 167% to $1.8 million. This was driven by a 2.3 percentage point increase in gross margin (to 49.3%) and reduced operating expenses.
• Expense Reduction: Operating expenses decreased 19.5% year-over-year. Sales and marketing expenses dropped 16.5%, and General and Administrative expenses dropped 11.7%, largely due to foreign exchange effects and cost reduction initiatives from the 2008 restructuring plan.
• Cash Flow Surge: Net cash provided by operating activities increased significantly to $4.3 million from $0.7 million, primarily due to a $2.7 million decrease in accounts receivable and improved net income.
• Restructuring: The Company recorded $55,000 in restructuring charges in Q1 2009 related to a new plan to relocate the Scie-Plas operation, compared to $0.8 million in Q1 2008.

Guidance, Outlook, and Risks

• Outlook: Management expects overall demand to remain soft outside of potential stimulus funding from the National Institute of Health (NIH). The Company plans to drive organic growth through new product launches (including a major product in Q2 2009) and direct marketing.
• Acquisition Strategy: The Company intends to pursue "tuck-under" acquisitions to support growth, leveraging its strong balance sheet.
• Foreign Exchange Risk: Approximately 58% of revenues are derived from non-U.S. operations. A strengthening U.S. dollar continues to negatively impact reported earnings and cash flows. The Company is using derivative instruments to hedge intercompany loans but does not designate them as accounting hedges.
• Liquidity and Credit Facility: The Company has a $20.0 million revolving credit facility maturing December 1, 2009, with no borrowings outstanding as of March 31, 2009. Management is negotiating a new facility but notes that prevailing interest rates are estimated to be 0.5% higher than current rates due to global credit market conditions.
• Stock Repurchases: The Company repurchased 434,074 shares for $1.2 million during the quarter. Approximately $6.2 million remains available under the current authorization.

Investor Verification Checklist

• Foreign Currency Impact: Verify the sensitivity of future earnings to U.S. dollar strength, given that 58% of revenue is international and organic growth was flat in constant currency.
• Credit Facility Renewal: Monitor the status of the new credit facility negotiations, as the current facility matures in December 2009 and market conditions may affect terms.
• Discontinued Operations: Confirm that no further earn-out payments or liabilities remain from the divestiture of the Capital Equipment Business segment (Genomic Solutions and Union Biometrica).
• Inventory Levels: Review inventory balances ($12.0 million) relative to sales trends to assess potential obsolescence risks in a soft economic environment.
• NIH Stimulus Timing: Assess the actual impact of NIH stimulus funding on order activity in subsequent quarters, as management cited this as a potential driver for later in the year.